Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RASTRIC
2023-509732-25-00Phase 2Completed
- Sponsor
- University Medical Center Utrecht
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of binimetinib, lapatinib and vinorelbine in colorectal cancer (CRC), sponsored by University Medical Center Utrecht. Primary endpoints: Dose-limiting toxicities and recommended phase 2 dose and Objective response rate (ORR). Started Sep 2024; status: completed.
02
Drugs
binimetiniblapatinibvinorelbine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2023-509732-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509732-25-00.